Nutriband Inc. (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch
- The opioid epidemic has prompted a re-evaluation of pain-management strategies, highlighting the importance of balancing effective treatment with abuse prevention
- Nutriband’s AVERSA(TM) Fentanyl represents a significant advancement in this domain
- The company’s strategic development of AVERSA Fentanyl follows a structured pharmaceutical lifecycle
As the opioid crisis continues to challenge public health systems, the need for innovative solutions has become increasingly apparent. Rather than relying solely on restrictive measures, companies such as Nutriband (NASDAQ: NTRB) are exploring technological advancements to mitigate abuse while ensuring patient access to necessary medications. Nutriband’s development of AVERSA(TM) Fentanyl, an abuse-deterrent transdermal patch, exemplifies this forward-thinking approach (https://nnw.fm/pjYVK ).
The opioid epidemic has prompted a reevaluation of pain-management strategies, highlighting the importance of balancing effective treatment with abuse prevention. Traditional methods often involve limiting prescriptions, which can inadvertently hinder patients with legitimate needs. Innovative pharmaceutical developments aim to address this by incorporating abuse-deterrent technologies, thereby reducing the potential for misuse without compromising therapeutic efficacy.
Nutriband’s AVERSA Fentanyl represents a significant advancement in this domain (https://nnw.fm/iWIZW ). By integrating aversive agents such as denatonium benzoate and capsaicin into the transdermal patch, the product is designed to deter abuse through alternative administration routes, such as chewing or injecting. This approach maintains the patch’s effectiveness for pain management while reducing its attractiveness for misuse.
The development of AVERSA follows a structured pharmaceutical lifecycle, beginning with feasibility studies to assess the integration of abuse-deterrent technology into existing fentanyl patch systems. Nutriband collaborated with Kindeva Drug Delivery, leveraging its U.S. Food and Drug Administration (“FDA”)-approved transdermal fentanyl patch system to incorporate the AVERSA technology. This partnership facilitated the adaptation of commercial manufacturing processes to accommodate the new formulation.
Following successful feasibility assessments, the focus shifted to scaling up manufacturing capabilities. Kindeva completed the validation of analytical methods required to handle the aversive agents on the commercial production line. This step was crucial in ensuring consistent quality and safety standards for the modified patch.
Concurrently, Nutriband prepared for the pivotal human abuse potential (“HAP”) clinical study, a phase 1 trial designed to evaluate the patch’s deterrent properties. This study is a critical component of the 505(b)(2) New Drug Application (“NDA”) pathway, which allows for a streamlined approval process by referencing existing data on approved drugs. Notably, this pathway requires only a single clinical trial, expediting the time to market (https://nnw.fm/BiNqA ).
To support these endeavors, Nutriband secured an $8.4 million private placement, earmarked for the commercial development of AVERSA Fentanyl through to NDA filing (https://nnw.fm/osdAP ). The company aims to submit the NDA to the FDA in the first quarter of 2025, positioning AVERSA Fentanyl as potentially the first abuse-deterrent transdermal opioid patch approved globally. The potential impact of AVERSA Fentanyl extends beyond regulatory milestones. Market analysis suggests that the product could achieve peak annual U.S. sales between $80 million and $200 million, reflecting the significant demand for safer opioid delivery systems.
Nutriband’s approach underscores the importance of innovation in addressing complex public health issues. By focusing on technological solutions that deter abuse while preserving access, the company exemplifies a balanced strategy in combating the opioid crisis. As AVERSA Fentanyl progresses through the development pipeline, it holds promise as a model for future pharmaceutical innovations aimed at mitigating drug abuse.
For more information, visit the company’s website at www.Nutriband.com.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://nnw.fm/NTRB
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- The opioid epidemic has prompted a re-evaluation of pain-management strategies, highlighting the importance of balancing effective treatment with abuse prevention
- Nutriband’s AVERSA(TM) Fentanyl represents a significant advancement in this domain
- The company’s strategic development of AVERSA Fentanyl follows a structured pharmaceutical lifecycle
As the opioid crisis continues to challenge public health systems, the need for innovative solutions has become increasingly apparent. Rather than relying solely on restrictive measures, companies such as Nutriband (NASDAQ: NTRB) are exploring technological advancements to mitigate abuse while ensuring patient access to necessary medications. Nutriband’s development of AVERSA(TM) Fentanyl, an abuse-deterrent transdermal patch, exemplifies this forward-thinking approach (https://nnw.fm/pjYVK ).
The opioid epidemic has prompted a reevaluation of pain-management strategies, highlighting the importance of balancing effective treatment with abuse prevention. Traditional methods often involve limiting prescriptions, which can inadvertently hinder patients with legitimate needs. Innovative pharmaceutical developments aim to address this by incorporating abuse-deterrent technologies, thereby reducing the potential for misuse without compromising therapeutic efficacy.
Nutriband’s AVERSA Fentanyl represents a significant advancement in this domain (https://nnw.fm/iWIZW ). By integrating aversive agents such as denatonium benzoate and capsaicin into the transdermal patch, the product is designed to deter abuse through alternative administration routes, such as chewing or injecting. This approach maintains the patch’s effectiveness for pain management while reducing its attractiveness for misuse.
The development of AVERSA follows a structured pharmaceutical lifecycle, beginning with feasibility studies to assess the integration of abuse-deterrent technology into existing fentanyl patch systems. Nutriband collaborated with Kindeva Drug Delivery, leveraging its U.S. Food and Drug Administration (“FDA”)-approved transdermal fentanyl patch system to incorporate the AVERSA technology. This partnership facilitated the adaptation of commercial manufacturing processes to accommodate the new formulation.
Following successful feasibility assessments, the focus shifted to scaling up manufacturing capabilities. Kindeva completed the validation of analytical methods required to handle the aversive agents on the commercial production line. This step was crucial in ensuring consistent quality and safety standards for the modified patch.
Concurrently, Nutriband prepared for the pivotal human abuse potential (“HAP”) clinical study, a phase 1 trial designed to evaluate the patch’s deterrent properties. This study is a critical component of the 505(b)(2) New Drug Application (“NDA”) pathway, which allows for a streamlined approval process by referencing existing data on approved drugs. Notably, this pathway requires only a single clinical trial, expediting the time to market (https://nnw.fm/BiNqA ).
To support these endeavors, Nutriband secured an $8.4 million private placement, earmarked for the commercial development of AVERSA Fentanyl through to NDA filing (https://nnw.fm/osdAP ). The company aims to submit the NDA to the FDA in the first quarter of 2025, positioning AVERSA Fentanyl as potentially the first abuse-deterrent transdermal opioid patch approved globally. The potential impact of AVERSA Fentanyl extends beyond regulatory milestones. Market analysis suggests that the product could achieve peak annual U.S. sales between $80 million and $200 million, reflecting the significant demand for safer opioid delivery systems.
Nutriband’s approach underscores the importance of innovation in addressing complex public health issues. By focusing on technological solutions that deter abuse while preserving access, the company exemplifies a balanced strategy in combating the opioid crisis. As AVERSA Fentanyl progresses through the development pipeline, it holds promise as a model for future pharmaceutical innovations aimed at mitigating drug abuse.
For more information, visit the company’s website at www.Nutriband.com.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://nnw.fm/NTRB
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
